Natco Pharma Limited Stock Fundamentals
| NATCOPHARM | 1,376 38.05 2.84% |
Natco Pharma Limited fundamentals help investors to digest information that contributes to Natco Pharma's financial success or failures. It also enables traders to predict the movement of Natco Stock. The fundamental analysis module provides a way to measure Natco Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Natco Pharma stock.
As of now, Natco Pharma's Operating Income is increasing as compared to previous years. The Natco Pharma's current EBIT is estimated to increase to about 17.8 B, while Interest Expense is projected to decrease to under 180 M. Natco | Select Account or Indicator |
Natco Pharma Limited Company Return On Equity Analysis
Natco Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Natco Pharma Return On Equity | 0.31 |
Most of Natco Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Natco Pharma Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Natco Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Natco Pharma Limited has a Return On Equity of 0.3123. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The return on equity for all India stocks is notably lower than that of the firm.
Natco Pharma Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Natco Pharma's current stock value. Our valuation model uses many indicators to compare Natco Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Natco Pharma competition to find correlations between indicators driving Natco Pharma's intrinsic value. More Info.Natco Pharma Limited is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.60 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Natco Pharma Limited is roughly 1.65 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Natco Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Natco Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Natco Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Natco Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Natco Pharma could also be used in its relative valuation, which is a method of valuing Natco Pharma by comparing valuation metrics of similar companies.Natco Pharma is currently under evaluation in return on equity category among its peers.
Natco Fundamentals
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.19 | ||||
| Profit Margin | 0.43 % | ||||
| Operating Margin | 0.55 % | ||||
| Current Valuation | 223.82 B | ||||
| Shares Outstanding | 179.11 M | ||||
| Shares Owned By Insiders | 50.90 % | ||||
| Shares Owned By Institutions | 14.39 % | ||||
| Price To Book | 3.45 X | ||||
| Price To Sales | 5.40 X | ||||
| Revenue | 40.02 B | ||||
| Gross Profit | 20.54 B | ||||
| EBITDA | 18.8 B | ||||
| Net Income | 13.88 B | ||||
| Cash And Equivalents | 4.14 B | ||||
| Total Debt | 3.86 B | ||||
| Book Value Per Share | 399.14 X | ||||
| Cash Flow From Operations | 12.52 B | ||||
| Earnings Per Share | 108.66 X | ||||
| Target Price | 1343.09 | ||||
| Number Of Employees | 4.02 K | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 246.37 B | ||||
| Total Asset | 69.06 B | ||||
| Retained Earnings | 44.66 B | ||||
| Working Capital | 30.51 B | ||||
| Annual Yield | 0 % | ||||
| Net Asset | 69.06 B | ||||
| Last Dividend Paid | 1.25 |
About Natco Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Natco Pharma Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Natco Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Natco Pharma Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 853 M | 923.4 M | |
| Total Revenue | 40 B | 42 B | |
| Cost Of Revenue | 8.6 B | 9.1 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Natco Stock
Natco Pharma financial ratios help investors to determine whether Natco Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Natco with respect to the benefits of owning Natco Pharma security.